Zura Bio Posts $25.8M Q3 Loss as Cash Drops to $187.7M
ZURA is trading near its 52-week low of $3.25 (11% above the low).
Summary
Zura Bio reported a Q3 net loss of $25.825 million, or -$0.20 per share, with operating expenses of $28.773 million and a pretax loss of $27.046 million. Cash and equivalents stood at $187.70 million at September 30, 2026, which the company says funds operations through 2028. That is down from the $205.1 million disclosed in the Q2 filing in August, a roughly $17 million quarterly burn. The loss is routine for a clinical-stage biotech, but the shrinking cash balance keeps the focus on the hidradenitis suppurativa Phase 2 program and whether upcoming data justify the spend. The 10-Q filed this morning carries the full detail behind these figures.
At the time of this announcement, ZURA was trading at $3.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $341.2M. The 52-week trading range was $3.25 to $7.44. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.